Loading
NASDAQHealthcareBiotechnology
Latest quote
$26.25
−$0.18 · -0.68%
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Previous close
$26.25
−$0.18 · -0.68%
Pre-market
$26.24
−$0.01 · -0.04%
Oct 8, 4:44 AM ET
Regular session · ET · Market data may be delayed.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Day range
Current $26.25
52-week range
Current $26.25
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
58
Mixed
Risk
66
High Risk
Momentum
51
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Day range
Current $26.25
52-week range
Current $26.25
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | — | 167.5M USD | — | — |
| Cost of goods sold | 2.4M USD | — | — | — |
| Gross profit | −2.4M USD | 167.5M USD | — | — |
| Research and development | 108.45M USD | 83.5M USD | 73.95M USD | 88.19M USD |
| Selling, general, and administrative | 34.45M USD | 26.42M USD | 24.61M USD | 22.83M USD |
| Operating expenses | 140.5M USD | 109.91M USD | 98.55M USD | 111.03M USD |
| Interest income | 11.78M USD | 4.65M USD | 1.97M USD | 2.03M USD |
| Depreciation and amortization | 2.4M USD | 3.3M USD | 4.09M USD | 3.82M USD |
| Operating income | −142.9M USD | 57.59M USD | −98.55M USD | −111.03M USD |
| Net income | −131.12M USD | 52.23M USD | −100.42M USD | −114.94M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$64.00
143.81% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI37.52M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM24.35M0.03%78.56B USD0.19%$277.7-1.29%
State Street SPDR S&P Pharmaceuticals ETFXPH9.59M1.97%462.1M USD0.35%$62.910.00%
Vanguard Extended Market ETFVXF8.75M0.01%95.4B USD0.05%$233.49-1.56%
iShares Russell 2000 Growth ETFIWO7.37M0.05%14.25B USD0.24%$355.37-1.43%
iShares Biotechnology ETFIBB6.85M0.07%10.4B USD0.44%$203.34+0.12%
Vanguard Russell 2000 ETFVTWO5.39M0.03%18B USD0.06%$112.21-1.26%
Schwab U.S. Small-Cap ETFSCHA5.09M0.02%22.01B USD0.03%$32.61-1.47%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
